Keros director granted RSUs and stock options
Keros Therapeutics director Mary Ann Gray received new equity awards.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Keros Therapeutics director Mary Ann Gray received new equity awards. She was granted 7,142 shares of common stock in the form of restricted stock units that fully vest on the earlier of June 3, 2027 or the 2027 annual meeting, subject to continued service. She also received options for 7,433 shares at an exercise price of $10.50 per share, vesting in equal quarterly installments over 12 months after June 3, 2026 and fully vested by the 2027 annual meeting. Following the RSU grant, she directly holds 12,392 common shares.
Insider Trade Summary
Grant/Award: 14,575 shares
Grant/Award
2 txns
Insider
GRAY MARY ANN
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 7,433 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 7,142 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 7,433 contracts (Direct);
Common Stock — 12,392 shares (Direct)
Footnotes (2)
- F1. Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 3, 2027 and (B) the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.
- F2. The option shall vest in equal quarterly installments over the 12 months following June 3, 2026, provided that the grant will in any case be fully vested on the date of Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.
Key Figures
RSU grant: 7,142 shares
Post-grant common shares: 12,392 shares
Stock options granted: 7,433 options
+4 more
7 metrics
RSU grant
7,142 shares
Restricted stock units granted on June 3, 2026
Post-grant common shares
12,392 shares
Common stock directly held after RSU award
Stock options granted
7,433 options
Stock options reported as acquired on June 3, 2026
Option exercise price
$10.50 per share
Conversion or exercise price of new stock options
Option expiration
June 2, 2036
Expiration date of reported stock options
RSU full vesting date
June 3, 2027
RSUs fully vest by this date or 2027 annual meeting
Option vesting schedule
Quarterly over 12 months
Equal quarterly vesting following June 3, 2026
Key Terms
restricted stock unit (RSU), Stock Option (right to buy), exercise price, annual meeting of stockholders, +1 more
5 terms
restricted stock unit (RSU) financial
"Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 3, 2027..."
A restricted stock unit (RSU) is a promise from a company to give an employee company shares (or cash equal to their value) at a future date if certain conditions are met, such as staying with the company or hitting performance targets. For investors, RSUs matter because when they convert into actual shares they increase the number of shares available and can create selling pressure as employees cash out—think of them as a future paycheck paid in company stock.
Stock Option (right to buy) financial
"Stock Option (right to buy) ... conversion_or_exercise_price: "10.5000"..."
exercise price financial
"conversion_or_exercise_price: "10.5000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
annual meeting of stockholders financial
"the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service..."
vesting financial
"The option shall vest in equal quarterly installments over the 12 months following June 3, 2026..."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Keros Therapeutics (KROS) director Mary Ann Gray report?
Mary Ann Gray reported receiving equity awards from Keros Therapeutics. She was granted 7,142 restricted stock units and stock options for 7,433 shares, both as compensation-related awards rather than open-market purchases or sales.
What are the key terms of Mary Ann Gray’s new stock options at Keros Therapeutics (KROS)?
She received stock options covering 7,433 Keros Therapeutics shares at a $10.50 exercise price. The options vest in equal quarterly installments over 12 months after June 3, 2026, and are fully vested by the 2027 annual meeting, subject to continued service.
When do Mary Ann Gray’s restricted stock units in Keros Therapeutics (KROS) fully vest?
The restricted stock units fully vest on the earlier of June 3, 2027 or the date of Keros Therapeutics’ 2027 annual meeting of stockholders. Vesting is conditioned on Mary Ann Gray continuing to provide service through the applicable date.
When do Mary Ann Gray’s Keros Therapeutics (KROS) stock options expire?
The stock options reported in the Form 4 expire on June 2, 2036. They vest in quarterly installments starting after June 3, 2026 and become fully vested by the 2027 annual meeting, assuming she continues to provide service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates